Bausch Health Companies Inc. BHC PHARMA
Company Overview
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, Czech Republic, Slovakia, Ukraine, Bulgaria, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Why Investors Should Care
Revenue has grown at a 16.6% CAGR over the past five years.
Operating margin of 27.2% supports profitability.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $10.27B (+6.7% YoY); net profit $157.00M.
- Trailing 12 Months Year-on-year growth — revenue +12.7%, earnings +70.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 16.6%, profit CAGR -0.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 16.57% |
| 1 Year: | 12.70% |
Compounded Profit Growth
| 5 Years: | -0.73% |
| 1 Year: | 70.40% |
Stock Price Performance
| 1 Year: | -10.32% |
| 6 Months: | +20.19% |
| 3 Months: | +25.83% |
| 1 Month: | +2.88% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)52.63 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 16.6% over 5 years.
- Generates positive free cash flow.
CONS
- Earnings shrank at -0.7% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BHC Bausch Health Companies Inc. PHARMA | 6.43 | -2.19 | $2.40B | 0.00% | 8.17% | -28.34% | 16.57% | -0.73% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 2.11B | 2.23B | 2.22B | 2.16B | 2.00B | 2.13B | 2.14B | 2.12B | 2.02B | 2.15B | 2.21B | 2.22B | 2.01B | 1.66B | 2.14B | 2.21B | 2.03B | 2.10B | 2.11B | 1.92B | 1.97B | 2.05B | 1.94B | 2.17B | 2.24B | 2.15B | 2.40B | 2.51B | 2.26B | 2.53B | 2.68B | 2.52B | 2.85B |
| Operating Income | 342.00M | 448.00M | 168.00M | 66.00M | 81.00M | -863.00M | 150.00M | 211.00M | 175.00M | 38.00M | -322.00M | -2.28B | -245.00M | 117.00M | 25.00M | 287.00M | 257.00M | 329.00M | -1.08B | 248.00M | -27.00M | 460.00M | -5.00M | -221.00M | -270.00M | 574.00M | 285.00M | 161.00M | 244.00M | 175.00M | 412.00M | 14.00M | 281.00M | 389.00M | 318.00M | 276.00M | 444.00M | 619.00M | -950.00M | 740.00M |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -152.00M | -326.00M | 71.00M | - | -610.00M | -595.00M | 188.00M | -69.00M | -145.00M | 399.00M | -201.00M | 26.00M | -378.00M | -64.00M | 10.00M | -85.00M | -58.00M | 148.00M | 179.00M | -1.42B | 258.00M |
| Diluted EPS | -0.15 | 0.14 | -1.12 | -1.08 | -0.88 | -3.49 | -1.47 | 1.79 | -0.11 | 3.69 | 1.45 | -7.36 | -2.49 | -1.00 | -0.98 | -0.15 | - | -0.14 | - | -0.43 | -0.92 | 0.20 | - | -1.71 | -1.66 | 0.52 | -0.19 | -0.40 | 1.10 | -0.55 | 0.07 | -1.03 | -0.17 | 0.03 | -0.23 | -0.16 | 0.40 | 0.48 | -3.82 | 0.68 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 757.18M | 820.43M | 1.18B | 2.43B | 3.48B | 5.77B | 8.21B | 10.45B | 9.67B | 8.72B | 8.38B | 8.60B | 8.03B | 8.43B | 8.12B | 8.76B | 9.62B | 10.27B |
| Operating Income | 124.11M | 181.15M | -110.08M | 299.96M | 79.70M | -409.50M | 2.00B | 1.53B | -566.00M | 102.00M | -2.38B | -203.00M | 676.00M | 450.00M | 454.00M | 963.00M | 1.55B | 1.81B |
| Net Income | - | 176.46M | -208.19M | 159.56M | -116.00M | -866.10M | 881.00M | -292.00M | -2.41B | 2.40B | -4.15B | -1.79B | -560.00M | -948.00M | -225.00M | -592.00M | -46.00M | 157.00M |
| Diluted EPS | 1.25 | 1.11 | -1.06 | 0.49 | -0.38 | -2.70 | 2.58 | -0.85 | -6.94 | 6.83 | -11.81 | -5.08 | -1.58 | -2.64 | -0.62 | -1.62 | -0.13 | 0.42 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 2.06B | 10.80B | 13.11B | 17.95B | 27.93B | 26.30B | 48.97B | 43.53B | 37.50B | 32.49B | 33.86B | 31.20B | 29.20B | 25.69B | 27.35B | 26.52B | 26.37B |
| Total Equity | 1.30B | 1.20B | 1.35B | 4.91B | 3.93B | 3.72B | 5.12B | 5.28B | 5.91B | 3.15B | 5.85B | 2.73B | 1.06B | 535.00M | -106.00M | -692.00M | -1.02B | -1.28B | -554.00M |
| Cash & Equivalents | 433.64M | 317.55M | 114.46M | 394.27M | 164.10M | 916.10M | 600.00M | 323.00M | 597.00M | 542.00M | 720.00M | 721.00M | 3.24B | 605.00M | 582.00M | 564.00M | 947.00M | 1.18B | 1.31B |
| Long Term Debt | - | - | 313.98M | 3.48B | 6.54B | 10.54B | 17.16B | 15.23B | 30.27B | 29.84B | 25.23B | 24.08B | 24.66B | 23.93B | 22.65B | 20.33B | 21.94B | 18.94B | 20.59B |
| Total Liabilities | - | - | 704.92M | 5.88B | 9.18B | 14.23B | 22.74B | 20.90B | 42.94B | 40.27B | 31.55B | 29.68B | 32.73B | 30.59B | 29.24B | 25.43B | 27.43B | 26.84B | 25.99B |
| Current Liabilities | - | - | 249.15M | 692.46M | 924.27M | 1.82B | 2.51B | 2.71B | 5.31B | 3.61B | 4.27B | 3.84B | 6.25B | 4.91B | 5.20B | 3.94B | 4.30B | 6.75B | 4.18B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 204.32M | 360.90M | 263.19M | - | 656.60M | 1.04B | 2.31B | 2.26B | 2.09B | 2.29B | 1.50B | 1.50B | 1.11B | 1.43B | -728.00M | 1.03B | 1.60B | 1.40B |
| Investing Cash Flow | -107.83M | -742.77M | 228.94M | - | -2.97B | -5.38B | -100.00M | -15.58B | -125.00M | 2.89B | -196.00M | -419.00M | -261.00M | 409.00M | -303.00M | -2.15B | -454.00M | -595.00M |
| Financing Cash Flow | -210.31M | 177.05M | -213.28M | - | 3.06B | 4.03B | -2.46B | 13.62B | -1.96B | -4.96B | -1.35B | 1.44B | -2.29B | -1.51B | -474.00M | 1.48B | -868.00M | -742.00M |
| Capital Expenditure | -22.00M | -7.42M | -16.82M | -58.52M | -107.60M | -115.30M | -292.00M | -235.00M | -235.00M | -171.00M | -157.00M | -270.00M | -302.00M | -269.00M | -218.00M | -215.00M | -337.00M | -397.00M |
| Free Cash Flow | 182.33M | 353.47M | 246.37M | - | 549.00M | 926.70M | 2.02B | 2.02B | 1.85B | 2.12B | 1.34B | 1.23B | 809.00M | 1.16B | -946.00M | 817.00M | 1.26B | 1.00B |
| Share Buybacks | 29.84M | - | 60.13M | 639.24M | 280.70M | 55.60M | 0 | 72.00M | 0 | 0 | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 16.4% | 22.1% | -9.3% | 12.4% | 2.3% | -7.1% | 24.4% | 14.6% | -5.9% | 1.2% | -28.4% | -2.4% | 8.4% | 5.3% | 5.6% | 11.0% | 16.1% | 17.7% |
| Net Margin % | - | 21.5% | -17.6% | 6.6% | -3.3% | -15.0% | 10.7% | -2.8% | -24.9% | 27.6% | -49.5% | -20.8% | -7.0% | -11.2% | -2.8% | -6.8% | -0.5% | 1.5% |
| ROE % | - | 13.0% | -4.2% | 4.1% | -3.1% | -16.9% | 16.7% | -4.9% | -76.4% | 41.1% | -151.8% | -168.2% | -104.7% | 894.3% | 32.5% | 57.9% | 3.6% | -28.3% |
| ROCE % | - | 10.0% | -1.1% | 2.5% | 0.5% | -1.6% | 8.5% | 3.5% | -1.4% | 0.3% | -8.3% | -0.7% | 2.6% | 1.9% | 2.1% | 4.2% | 7.8% | 8.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | PAULSON & CO. INC. | 19.58% | 73.26M | $415.36M |
| 2 | Goldentree Asset Management LP | 9.27% | 34.67M | $196.55M |
| 3 | Royal Bank of Canada | 2.90% | 10.83M | $61.42M |
| 4 | Healthcare of Ontario Pension Plan Trust Fund | 2.14% | 8.00M | $45.36M |
| 5 | Vanguard Capital Management LLC | 2.00% | 7.47M | $42.33M |
| 6 | Goldman Sachs Group Inc | 1.66% | 6.23M | $35.30M |
| 7 | MFN Partners Management, LP | 1.60% | 6.00M | $34.02M |
| 8 | SG Americas Securities, LLC | 1.48% | 5.54M | $31.39M |
| 9 | Acadian Asset Management. LLC | 1.47% | 5.48M | $31.09M |
| 10 | Kohlberg Kravis Roberts & Co. L.P. | 1.40% | 5.24M | $29.68M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BHC
Bausch Health takes YUN skincare to Mexico and four new markets - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxNcUplaTBzVU5IZF9nQllobHdZVlVtS1hMX3RKV2NmalpzU2hiZlBUUnNvd1J6cDJvS2U0ZGdHT2x5d0VIVlByNXNucXlIRDRsVHhOdFRJTFNfcGQxQ3pONDdYaFl3aTN1bEV2X3pTUUkwVWJJSGhtSEJoc2plMGVVc0Q3emdsMjktZ0NDZG…
BHC Looks 11.9% Undervalued on GF Value™ - gurufocus.com
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxNanZWUFdNbzl1YnpjMFhMT1pxNkJiTDJXSmVhaVRQYnVtTkwwWXNFV0toODNZTEQ0NHBYWV91TVYyUzQ5bFd2MC1yM05aSTM5SXBVNk1NTjI4dHpYYk9ZUlV3RjNtWERLdjU2NG5WYjI4ZWxIX1V0VTJaLVlTQm04MkZR?oc=5" target=…
Bausch Health Stock (BHC) Opinions on Q2 2026 Earnings Results | BHC Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQU1gxZEoyX1loUVI3d2VJcHNmSmV5ZUI2VDVhVFE2TzUwcWNKSkVEU0NZdExfYzFBNlc5WTFhcjJNZUx2VXlTUDVJc3RGdUZzNnFmRVlfMnFUYU1qN2VGMWt4MjFUbmFiQVdJQ1piNndqMkt0Z3lxdkJDLXdKZXV4ZDRjbERNMnNTZmRKd1…
BHC|Bausch Health Companies Inc|Price:6.760|Chg%:-0.070 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTFBNaDFvN29fRTdLZWlJam1XckVONXc5UHFnVS1JQTdhaEkwOFlILUZPLTNtbkY2aGd1SXhQaXFKX0FZdDFockJEZFJsa1dTOGVaM3JwUHZnWFNqU1V5V3o0eG1vRHpSNVlKcTVWeQ?oc=5" target="_blank">BHC|Bausch Health Com…
BHC Stock Soars As Earnings Beat Fuels Fresh Uptrend - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxNdEVyUng1YnNxWVowMkxlcndITGRCNzZ5ZjN2bG1meGt0TGgxdHcxN18zWmIweTIwcWo2WE5NNktVSDNmTFJPMERxNUdHQ3FQckpSMm1HTUJNV3BCSkpxMEUzeDIzUnZQaE1nRUo2dDZSa09oMXlNZFRHYzYtTGI0WG1pbmYtQQ?oc=5" t…
Bausch Health Companies Inc. (BHC): Billionaire Howard Marks Likes This Pharma Stock - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPbHJXVDlUWnlQMVF6bWdOaE83dV9kZE8zczhob0dOM3RlTkdrYUhGNnRzbjdqZVVlRHhCWGQ1TWFjLWJKaGp4MElYSjUxX2dQWERYN2hGZDc4WW52NU5naDAtWExXM2hfdE10MEpVV0diZ2VpRzZ3aG1TMHlTY0NXQW90OGpKNTlqT0hPTU…
BHC — Frequently Asked Questions
What is the current share price of Bausch Health Companies Inc. (BHC)?
As of 2026-09-19 21:16 PDT, Bausch Health Companies Inc. (BHC) trades at $6.43 on NYSE. Its 52-week range is $4.43 to $8.34.
What is the market capitalisation of BHC?
Bausch Health Companies Inc. (BHC) has a market capitalisation of $2.40B on NYSE.
What is the P/E ratio of BHC?
BHC trades at a trailing price-to-earnings (P/E) ratio of -2.19. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -1.30.
What is the return on equity (ROE) of BHC?
BHC has a return on equity (ROE) of -28.34%. Its return on capital employed (ROCE) is 8.17%.
Is BHC a good stock to buy?
This page provides a data-driven analysis of Bausch Health Companies Inc. (BHC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.